<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545815</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-PLAGH-BT-028</org_study_id>
    <nct_id>NCT03545815</nct_id>
  </id_info>
  <brief_title>Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.</brief_title>
  <official_title>Phase I Study to Evaluate Treatment of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Chimeric Antigen Receptor (CAR) T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple solid tumors have positive targets of mesothelin expressed on the surfaces of the&#xD;
      tumor cells, we use the technique of CRISPR-Cas9 to knocked out the PD-1 and TCR of chimeric&#xD;
      antigen receptor (CAR) T cells to effect the immuno-microenvironment around tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To evaluate the feasibility and safety of CRISPR-Cas9 mediated PD-1 and TCR gene-knocked&#xD;
           out chimeric antigen receptor (CAR) T cells in patients with mesothelin positive&#xD;
           multiple solid tumors.&#xD;
&#xD;
        2. To evaluate the duration of in vivo persistence of transferred CAR-T cells.&#xD;
&#xD;
        3. To observe and measure anti-tumor responses for patients with detectable mesothelin&#xD;
           positive tumor lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>study of related adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Grade 3 signs/symptoms, toxicities and clinical</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical responses to anti-mesothelin cell infusions</measure>
    <time_frame>24 weeks</time_frame>
    <description>Disease control rate(DCR)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>anti-mesothelin CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de- escalation.&#xD;
Patients receive anti-mesothelin-CAR T cells on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-mesothelin CAR-T cells</intervention_name>
    <description>Cells will be infused on day 0.</description>
    <arm_group_label>anti-mesothelin CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed with mesothelin positive multiple solid tumors.&#xD;
&#xD;
          2. Failure of at least one prior standard of care chemotherapy for advanced stage&#xD;
             disease.&#xD;
&#xD;
          3. Subjects must have measureable disease as defined by RECIST 1.1 criteria or modified&#xD;
             RECIST criteria.&#xD;
&#xD;
          4. Patients &gt; 18 years of age.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.&#xD;
&#xD;
          6. Life expectancy &gt; 12 weeks.&#xD;
&#xD;
          7. Satisfactory organ and bone marrow function as defined by the following (of note, the&#xD;
             minimal blood counts should be in the absence of transfusion or cytokine support):&#xD;
&#xD;
             i. Absolute neutrophil count &gt; 1,000/μl ii. Platelets &gt;75,000/μl iii. Hemoglobin &gt; 9&#xD;
             g/dL iv. Bilirubin &lt; 2.0x the institutional normal upper limit unless secondary to&#xD;
             bile duct obstruction by tumor v. Creatinine &lt; 1.5x the institutional normal upper&#xD;
             limit vi. Albumin ≥2 vii. Serum alanine aminotransferase (ALT) or aspartate&#xD;
             aminotransferase (AST) &lt; 5x the institutional normal upper limit viii. Cardiac&#xD;
             ejection fraction of &gt;55% as measured by resting echocardiogram, with no significant&#xD;
             pericardial effusion.&#xD;
&#xD;
          8. Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤&#xD;
             1.5 and a PTT &lt; 1.2 time the upper limit of normal unless the patient is&#xD;
             therapeutically anti-coagulated for history of cancer-related thrombosis and has&#xD;
             stable coagulation parameters.&#xD;
&#xD;
          9. Ability to understand and the willingness to provide written informed consent.&#xD;
&#xD;
         10. Male and Female subjects of reproductive potential agree to use approved contraceptive&#xD;
             methods (e.g. birth control pills, barrier device, intrauterine device, abstinence)&#xD;
             and abstain from other methods of conception during the study and for 6 months&#xD;
             following the study cell infusion or proof of sterility.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Sarcomatoid MPM histology which is known in the literature to not express mesothelin;&#xD;
             biphasic MPM is also excluded.&#xD;
&#xD;
          2. This refers to non-commercially approved investigational drugs different than those&#xD;
             used in this protocol.Participated in any other trial in which receipt of an&#xD;
             investigational study drug occurred within 28 days prior to enrollment and anticipated&#xD;
             treatment with another investigational product while on study.&#xD;
&#xD;
          3. Anticipated need for systemic chemotherapy within 2 weeks before apheresis and&#xD;
             infusion of CART-meso cells.&#xD;
&#xD;
          4. Active invasive cancer other than the one of the three cancers in this study. Patients&#xD;
             with active non-invasive cancers (such as non-melanoma skin cancer, superficial&#xD;
             cervical and bladder and prostate cancer with PSA level &lt; 1.0) are not&#xD;
             excluded.CART-meso in mesothelin expressing cancers&#xD;
&#xD;
          5. HIV, HCV, or HBV infections&#xD;
&#xD;
          6. Active autoimmune disease (including but not limited to: systemic lupus&#xD;
             erythromatosis, Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple&#xD;
             sclerosis, inflammatory bowel disease, etc.) requiring immunosuppressive therapy&#xD;
             within the past 4 weeks, with exception of thyroid replacement.&#xD;
&#xD;
          7. Patients with ongoing or active infection.&#xD;
&#xD;
          8. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be&#xD;
             on a stable low dose of steroids (&lt;10mg equivalent of prednisone) for chronic&#xD;
             respiratory conditions.&#xD;
&#xD;
          9. Patients requiring supplemental oxygen therapy.&#xD;
&#xD;
         10. Prior therapy with gene modified cells.&#xD;
&#xD;
         11. Previous experimental therapy with SS1 moiety, murine or chimeric antibodies (human&#xD;
             and humanized antibodies are allowed).&#xD;
&#xD;
         12. History of allergy to murine proteins&#xD;
&#xD;
         13. History of allergy or hypersensitivity to study product excipients (human serum&#xD;
             albumin, DMSO, and Dextran 40)&#xD;
&#xD;
         14. Any clinically significant pericardial effusion; CHF (NY Heart Association Grade&#xD;
             II-IV) or cardiovascular condition that would preclude assessment of mesothelin&#xD;
             induced pericarditis or that may worsen as a result of toxicities expected for this&#xD;
             study. This determination will be made by a cardiologist.&#xD;
&#xD;
         15. Any clinically significant pleural or peritoneal effusion that cannot be drained with&#xD;
             standard approaches. An indwelling drainage device placed prior to enrollment is&#xD;
             acceptable.&#xD;
&#xD;
         16. Pregnant or breastfeeding women. Female study participants of reproductive potential&#xD;
             must have a negative urine pregnancy test of enrollment. A serum pregnancy test will&#xD;
             be performed within 2 weeks before infusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wweidong Han, Dr.</last_name>
    <phone>86-10-13651392893</phone>
    <email>hanwdrsw@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong Han</last_name>
      <phone>86-10-13651392893</phone>
      <email>hanwdrsw@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>mesothelin, CRISPR-Cas9, PD-1, TCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

